|
|
|
Stem Cell Related Patent Number US5530178
| Title: | Mutant mouse lacking CD8 surface marker | | Inventors: | Mak, Tak W.; Toronto, Canada | | Summary: | This invention introduces a mutant mouse lacking CD8 on the surface of T lymphocytes. Elucidated herein are properties of a mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface which has been generated by disruption of the Lyt-2 gene and homologous recombination such that CD8+ T lymphocytes are not present in peripheral lymphoid organs, but the CD4+ T lymphocyte population remains unaltered. Claims of the invention include a decreased cytotoxic response of T lymphocytes in such mice against alloantigens and viral antigens, but an unaffected proliferative response against alloantigens and B lymphocytes. Therapeutic and experimental applications of such mice are included for use as models of diseases of the immune system and in drug development. | | Abstract: | A mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface has been generated by disrupting the Lyt-2 gene using embryonic stem cell technology. In these mammals, for example, mice, CD8.sup.+ T lymphocytes are not present in peripherial lymphoid organs, but the CD4.sup.+ T lymphocyte population seems to be unaltered. Cytotoxic response of T lymphocytes from these mice against alloantigens and viral antigens is dramatically decreased. Proliferative response against alloantigens and in vivo help to B lymphocytes, however, are not effected. These mice should be useful for drug development and for studies of diseases of the immune system such as, autoimmunity, immunodeficiency, transplant rejection and tumor rejection. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5530178 | | Application Number: | US1993000097930 | | Date Filed: | 28/07/1993 | | Date Published: | 25/06/1996 | | Assignee: | The Ontario Cancer Institute, Toronto, Canada |
|
|
